CLAIMS

1. An antisense oligonucleotide which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 98% complementarity to position 30654-30745 of SEQ ID NO: 1 (Region A 693 in Table 1) or position 11482-11535 of SEQ ID NO: 1 (Region A321 in Table 1).

2. The oligonucleotide of claim 1, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 46, 47, 48, 221, 222, 223, 224, 225, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 304, 305,

585, 586, 587, 588, 589625, 626, 627, 628, 629, 630, 631 632, 698, 699, 700, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, and 718733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807.

3. The oligonucleotide of claim 1 or 2, wherein the oligonucleotide comprises or consists of SEQ ID NO: 626.

4. The oligonucleotide of claim 1 or 2, wherein the oligonucleotide comprises or consists of SEQ ID NO: 585.

5. The oligonucleotide of any one of claims 1 to 3, comprising one or more 2' sugar modified nucleoside.

6. The oligonucleotide of claim 5, wherein the one or more 2' sugar modified nucleoside is independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides.

7. The oligonucleotide of claim 5 or 6, wherein the one or more modified nucleoside is a LNA nucleoside.

8. The oligonucleotide of any one of claims 1 to 7, where the oligonucleotide comprises at least one modified internucleoside linkage.

9. The oligonucleotide of claim 8, wherein the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages.

10. The oligonucleotide of any one of claims 1 to 9, wherein the oligonucleotide is capable of recruiting RNase H.

11. The oligonucleotide of claim 10, wherein the oligonucleotide is a gapmer.

12. The oligonucleotide of any one of claims 1 to 11, wherein the oligonucleotide is selected from the group consisting of CMP ID NO: 46_1, 47_1, 48_1, 48_2, 48_3, 48_4, 48_5, 48_6, 48_7,

221_1, 222_1, 223_1, 224_1, 225_1, 289_1, 290_1, 291_1, 292_1, 293_1, 294_1, 295_1, 296_1, 297_1, 298_1, 299_1, 300_1, 301_1, 302_1, 303_1, 304_1, 304_10, 304_2, 304_3, 304_4, 304_5, 304_6, 304_7, 304_8, 304_9, 304_11, 304_12, 304_13, 304_14, 304_15, and 305_1,

585_1, 585_2, 585_3, 585_4, 585_5, 585_6, 585_7, 585_8, 585_9, 585_10, 585_11, 585_12, 585_13, 585_14, 586_1, 586_2, 586_3, 586_4, 586_5, 586_6, 586_7, 586_8, 586_9, 586_10, 586_11, 586_12, 586_13, 586_14, 587_1, 587_2, 587_3, 587_4, 587_5, 587_6, 587_7, 587_8, 587_9, 587_10, 587_11, 587_12, 587_13, 587_14, 588_1, 588_2, 588_3, 588_4, 588_5, 588_6, 588_7, 588_8, 588_9, 588_10, 588_11, 588_12, 588_13, 588_14, 589_1, 589_2, 589_3, 589_4, 589_5, 589_6, 589_7, 589_8, 589_9, 589_10, 589_11, 589_12, 589_13, 589_14,

625_1, 625_2, 625_3, 625_4, 625_5, 625_6, 625_7, 625_8, 625_9, 625_10, 625_11, 625_12, 625_13, 625_14, 626_1, 626_2, 626_3, 626_4, 626_5, 626_6, 626_7, 626_8, 626_9, 626_10, 626_11, 626_12, 626_13, 626_14, 627_1, 627_2, 627_3, 627_4, 627_5, 627_6, 627_7, 627_8, 627_9, 627_10, 627_11, 627_12, 627_13, 627_14, 628_1, 628_2, 628_3, 628_4, 628_5, 628_6, 628_7, 628_8, 628_9, 628_10, 628_11, 628_12, 628_13, 628_14, 629_1, 629_10, 629_11, 629_2, 629_3, 629_4, 629_5, 629_6, 629_7, 629_8, 629_9, 629_12, 629_13, 629_14, 629_15, 629_16, 630_1, 630_2, 630_3, 631_1, 631_10, 631_2, 631_3, 631_4, 631_5, 631_6, 631_7, 631_8, 631_9, 631_11, 631_12, 631_13, 631_14, 631_15, 632_1, 632_2, 632_3, 632_4, 632_5, 632_6, 632_7, 632_8, 632_9, 632_10, 632_11, 632_12, 632_13, 632_14,

698_1, 698_2, 698_3, 698_4, 698_5, 699_1, 699_2, 699_3, 699_4, 699_5, 700_1, 700_2, 700_3, 700_4, 700_5, 701_1, 701_2, 701_3, 701_4, 701_5, 702_1, 702_2, 702_3, 702_4, 702_5, 703_1, 703_2, 703_3, 703_4, 703_5, 704_1, 704_2, 704_3, 704_4, 704_5, 705_1, 705_2, 705_3, 705_4, 705_5, 706_1, 706_2, 706_3, 706_4, 706_5, 707_1, 707_2, 707_3, 707_4, 707_5, 708_1, 708_2, 708_3, 708_4, 708_5, 709_1, 709_2, 709_3, 709_4, 709_5, 710_1, 710_2, 710_3, 710_4, 710_5, 711_1, 711_2, 711_3, 711_4, 711_5, 712_1, 712_2, 712_3, 712_4, 712_5, 713_1, 713_2, 713_3, 713_4, 713_5, 714_1, 714_2, 714_3, 714_4, 714_5, 715_1, 715_2, 715_3, 715_4, 715_5, 716_1, 716_2, 716_3, 716_4, 716_5, 717_1, 717_2, 717_3, 717_4, 717_5, 718_1, 718_2.

13. The oligonucleotide of claim 12, wherein the oligonucleotide comprises or consists of CMP ID NO: 626_7.

14. The oligonucleotide of claim 12, wherein the oligonucleotide comprises or consists of CMP ID NO: 585_1.

15. A conjugate comprising the oligonucleotide of any one of claims 1-14, and at least one conjugate moiety covalently attached to said oligonucleotide.

16. A pharmaceutical composition comprising the oligonucleotide of any one of claims 1 to 14 or the conjugate of claim 15 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.

17. An *in vitro* method for inducing UBE3A expression in a target cell where expression of paternal UBE3A is suppressed, said method comprising administering an oligonucleotide of any one of claims 1-14 or the conjugate according to claim 15 or the pharmaceutical composition of claim 16 in an effective amount to said cell.

18. The method according to claim 17, wherein the expression of UBE3A is increased by at least 40% compared to a control.

19. The method according to claim 17, wherein the level of the SNHG14 transcript downstream of SNORD109B is reduced by at least 30% compared to a control.

20. The method according to any one of claims 17-19, wherein the target cell is a neuronal cell.

21. The method according to any one of claims 17-20, wherein the expression of SNORD115 is not significantly affected compared to a control.

22. The oligonucleotide of any one of claims 1 to 14 or the conjugate according to claim 15 or the pharmaceutical composition of claim 16 for use in the treatment or prevention of Angelman syndrome.

23. Use of the oligonucleotide of any one of claims 1 to 14 or the conjugate according to claim 15 or the pharmaceutical composition of claim 16, for the preparation of a medicament for treatment or prevention of Angelman syndrome.